Rate My Professor Tim Schlub

Tim Schlub has co-authored impactful publications in prestigious journals, advancing understanding of viral persistence and immune protection. Key works include "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection" (Nature Medicine, 2021), which demonstrates the strong correlation between antibody levels and protection against COVID-19. He contributed to "Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis" (The Lancet Microbe, 2022), analyzing protection against variants. In HIV research, notable papers are "Identification of genetically intact HIV-1 proviruses in specific CD4+ T cells from effectively treated participants" (Cell Reports, 2017), "HIV persists throughout deep tissues with repopulation from multiple anatomical sources" (The Journal of Clinical Investigation, 2020), and "HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs" (Cell Host & Microbe, 2019). Additional contributions encompass "Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19" (Nature Communications, 2021), "Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection" (Emerging Infectious Diseases, 2023), "Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited CCR5 expression" (Nature Medicine, 2011), "Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration" (Ophthalmology, 2014), and "Reducing chimera formation during PCR amplification to ensure accurate genotyping" (Gene, 2010). Schlub frequently collaborates with researchers including Deborah Cromer, A. Reynaldi, and A.K. Wheatley on these topics. His research informs strategies for HIV cure and COVID-19 vaccine efficacy.